Activation of P-TEFb by Androgen Receptor-Regulated Enhancer RNAs in Castration-Resistant Prostate Cancer

Yu Zhao(Mayo Clinic), Liguo Wang(Mayo Clinic), Shancheng Ren(Second Military Medical University), Lan Wang(Mayo Clinic), Patrick R. Blackburn(Mayo Clinic), Melissa S. McNulty(Mayo Clinic), Xu Gao(Second Military Medical University), Meng Qiao(Second Military Medical University), Robert L. Vessella(University of Washington), Manish Kohli(Mayo Clinic), Jun Zhang(Mayo Clinic), R. Jeffrey Karnes(Mayo Clinic), Donald J. Tindall(Mayo Clinic), Youngsoo Kim(Ionis Pharmaceuticals (United States)), Robert A. MacLeod(Ionis Pharmaceuticals (United States)), Stephen C. Ekker(Mayo Clinic), Tiebang Kang(Sun Yat-sen University), Yinghao Sun(Second Military Medical University), Haojie Huang(Mayo Clinic)
Cell Reports
April 1, 2016
Cited by 132Open Access
Full Text

Abstract

The androgen receptor (AR) is required for castration-resistant prostate cancer (CRPC) progression, but the function and disease relevance of AR-bound enhancers remain unclear. Here, we identify a group of AR-regulated enhancer RNAs (e.g., PSA eRNA) that are upregulated in CRPC cells, patient-derived xenografts (PDXs), and patient tissues. PSA eRNA binds to CYCLIN T1, activates P-TEFb, and promotes cis and trans target gene transcription by increasing serine-2 phosphorylation of RNA polymerase II (Pol II-Ser2p). We define an HIV-1 TAR RNA-like (TAR-L) motif in PSA eRNA that is required for CYCLIN T1 binding. Using TALEN-mediated gene editing we further demonstrate that this motif is essential for increased Pol II-Ser2p occupancy levels and CRPC cell growth. We have uncovered a P-TEFb activation mechanism and reveal altered eRNA expression that is related to abnormal AR function and may potentially be a therapeutic target in CRPC.


Related Papers

No related papers found

Powered by citation graph analysis